News Detail

Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03

PUBT · 2d ago

Listen to the news

Rein Therapeutics enrolls 8 patients in Phase 2 IPF trial for LTI-03

Rein Therapeutics reported accelerated enrollment in Phase 2 RENEW study of LTI-03 for idiopathic pulmonary fibrosis.
Study enrolled 8 patients to date, with 2 more expected this week.
Enrollment started in March 2026, with additional patients being added on a regular basis.
Trial sites are active in United States, Australia, Poland, with United Kingdom and Germany expected to open soon.
No clinical results have been presented yet, with update focused on enrollment progress and site expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290800PRIMZONEFULLFEED9708567) on April 29, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.